Last week, Australia and the USA announced that they would begintrialsofanHlNl vaccine.Vaccination against H1N1 will be an important development in controlling the impact of the pandemic. However, several thorny issues exist around vaccine manufacture and approval.All countries will require the vaccine but current global manufacturing capacity will not be able to meet this demand. Additionally, expertsthinkthat individuals might need two doses of the vaccine instead of one, reducing capacity further. Vaccine manufacturers are also struggling to produce good vaccine yields with the H1N1 seed virus.
展开▼
